Home LiteratureArticle Details
PMID: 2428045 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.

Zalman LS, Wood LM, Müller-Eberhard HJ

Abstract

Erythrocytes are poorly lysed by homologous complement, whereas they are readily lysed by heterologous complement. This phenomenon had been attributed to an interference by the cell surface with the action of complement components C8 and C9. To isolate the responsible membrane constituent, detergent-solubilized human erythrocyte (EH) membranes were subjected to affinity chromatography by using human C9-Sepharose. The isolated protein had a mass of 38 kDa and, incorporated into liposomes, was highly effective in inhibiting complement-mediated channel expression, including the C5b-8, membrane attack complex, and tubular polymer of C9 channels. Antibody produced to the 38-kDa protein caused a 20-fold increase in reactive lysis of EH by isolated C5b6, C7, C8, and C9. The antibody did not enhance C5b-7 uptake, but it affected C9 binding to the target cell membrane. Antibody to human decay-accelerating factor, used as a control, had no effect on reactive lysis of EH. Anti-38-kDa protein did not enhance the action on EH of C8 and C9 from other species, indicating that the action of this regulatory protein is species specific. It was therefore termed homologous restriction factor (HRF). Blood cells other than erythrocytes, such as polymorphonuclear leukocytes, also exhibited cell-surface HRF activity. In immunoblots of freshly isolated EH membranes, anti-38-kDa HRF detected primarily a 65-kDa protein, suggesting that the 38-kDa protein constitutes an active fragment of membrane HRF. Because of the specific binding reaction observed between HRF and C8 or C9, HRF was tested with anti-human C8 and anti-human C9. A limited immunochemical relationship of HRF to C8 and C9 could be established and solid-phase anti-C9 proved an efficient tool for the isolation of HRF from solubilized EH membranes.

MeSH Terms
Blood Proteins/pharmacology CD55 Antigens Complement C8/immunology Complement C9/immunology Complement Inactivator Proteins/isolation & purification Complement Membrane Attack Complex Complement System Proteins Erythrocyte Membrane/analysis Hemolysis Humans Liposomes Membrane Proteins/immunology,isolation & purification Neutrophils/analysis
Chemicals
Blood Proteins CD55 Antigens Complement C8 Complement C9 Complement Inactivator Proteins Complement Membrane Attack Complex Liposomes Membrane Proteins Complement System Proteins
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Zalman L S
Wood L M
Müller-Eberhard H J
References (24)
24 references, click to expand
  1. Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action.
    Immunochemistry. 1969 May;6(3):405-19 PMID: 5786934
  2. Mechanism of cytotoxicity of human large granular lymphocytes: relationship of the cytotoxic lymphocyte protein to the ninth component (C9) of human complement.
    Proc Natl Acad Sci U S A. 1986 Jul;83(14):5262-6 PMID: 3460090
  3. The membrane attack mechanism of complement: the three polypeptide chain structure of the eigth component (C8).
    J Exp Med. 1976 May 1;143(5):1131-9 PMID: 1262784
  4. Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity.
    J Immunol. 1977 Oct;119(4):1482-5 PMID: 894048
  5. Structural similarities between C6 and C7 of human complement.
    J Immunol. 1979 Sep;123(3):1071-7 PMID: 381516
  6. Membrane attack complex of complement: a structural analysis of its assembly.
    J Exp Med. 1980 Feb 1;151(2):301-13 PMID: 7356725
  7. The ninth component of human complement: purification and physicochemical characterization.
    J Immunol. 1980 Mar;124(3):1291-6 PMID: 6766971
  8. Specificity of diffusion channels produced by lambda phage receptor protein of Escherichia coli.
    Proc Natl Acad Sci U S A. 1980 Jan;77(1):167-71 PMID: 6444720
  9. Complement lysis of human erythrocytes. III. Differing effectiveness of human and guinea pig C9 on normal and paroxysmal nocturnal hemoglobinuria cells.
    J Immunol. 1980 Nov;125(5):2063-8 PMID: 6776186
  10. Homologous species restriction in lysis of erythrocytes by terminal complement proteins.
    Proc Natl Acad Sci U S A. 1981 Aug;78(8):5118-21 PMID: 6946459
  11. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.
    J Immunol. 1982 Jul;129(1):184-9 PMID: 6211481
  12. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
    Proc Natl Acad Sci U S A. 1983 Aug;80(16):5066-70 PMID: 6576376
  13. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
    Proc Natl Acad Sci U S A. 1983 Sep;80(17):5430-4 PMID: 6225118
  14. Mechanism of insertion of diphtheria toxin: peptide entry and pore size determinations.
    Proc Natl Acad Sci U S A. 1984 Jun;81(11):3341-5 PMID: 6328510
  15. Circular polymerization of the membranolytic ninth component of complement. Dependence on metal ions.
    J Biol Chem. 1984 Aug 25;259(16):10569-73 PMID: 6432783
  16. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    J Exp Med. 1984 Nov 1;160(5):1558-78 PMID: 6238120
  17. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    J Immunol. 1985 Jan;134(1):506-11 PMID: 3964820
  18. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
    Proc Natl Acad Sci U S A. 1985 May;82(9):2980-4 PMID: 2581259
  19. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
    J Clin Invest. 1985 Jun;75(6):2074-84 PMID: 4008653
  20. Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization.
    Proc Natl Acad Sci U S A. 1985 Aug;82(16):5520-4 PMID: 3860874
  21. Functional domains of the alpha subunit of the eighth component of human complement: identification and characterization of a distinct binding site for the gamma chain.
    Biochemistry. 1985 Aug 13;24(17):4603-7 PMID: 4063342
  22. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.
    J Immunol. 1986 Mar 1;136(5):1772-6 PMID: 2419413
  23. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
    J Immunol. 1986 Mar 1;136(5):1777-82 PMID: 2419414
  24. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
1986-09-00
Pages
6975-9
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC386634
Subset
IM
Grants
NIAID NIH HHS · AI 17354 · United States
NCI NIH HHS · CA 27489 · United States
NHLBI NIH HHS · HL 16411 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com